Over 36 percent of inspected drug-making units had to be shut: CDSCO chief

"The issues in the Indian pharma industry relate to "non-compliance which leads to quality issues," CDSCO Chief

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-06-29 09:00 GMT | Update On 2024-08-05 19:22 GMT

Bengaluru: India's drug regulator reported that over 36 percent of the 400 drug manufacturing units inspected since last year have been directed to close. This action follows heightened scrutiny prompted by deaths associated with sub-standard cough syrups.

India, known as a global pharmaceutical hub due to its vast drug production, is actively working to rebuild trust after Indian-manufactured cough syrups were implicated in child deaths in Gambia, Uzbekistan, and Cameroon.

According to a Reuters report, India's Central Drugs Standard Control Organization (CDSCO) chief Rajeev Raghuvanshi said that after one and a half years of inspections, he was "not very happy to say that more than 36 per cent of them (manufacturing units) had to be closed."

The issues in the Indian pharma industry relate to "non-compliance which leads to quality issues," he told an event in Mumbai.

He did not elaborate or name any companies.

Cough syrups made in India and Indonesia have been linked to the deaths of more than 300 children globally. The medicines were found to contain high levels of two known toxins, diethylene glycol and ethylene glycol, leading to acute kidney injury and death.

India is the world's third largest maker of drugs by volume after the United States and China. India's pharma export sales are expected to reach $55 billion by 2030, according a government-backed trade body Pharmaceuticals Export Promotion Council of India (Pharmexcil). Export sales in 2023-2024 were $27.85 billion.

Prime Minister Narendra Modi's government late last year also issued revised guidelines to ensure compliance with global standards and made it mandatory for all of country's drug manufacturing units to adhere to them.

"We have not had any complaint from World Health Organization (WHO) or any other agency since last July .. we've been able to control the issues that were happening from a quality point of view," Raghuvanshi said.

Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Over 36 percent of inspected drug-making units had to be shut: CDSCO chief

"The issues in the Indian pharma industry relate to "non-compliance which leads to quality issues," CDSCO Chief

Similar News

Wockhardt Misses NPPA Clearance for Nafithromycin, Faces Questions on Patent Validity

Ajanta Pharma Told to Revise BE Study Protocol for Cilnidipine, Metoprolol FDC

Zydus Gets CDSCO Panel Nod to Market Sodium Chloride Nebuliser Solution

SC doors knocked for child deaths linked to contaminated cough syrup, CBI probe demanded

AstraZeneca Pharma India bags CDSCO nod for expanded use of Trastuzumab Deruxtecan in HER2-Positive Solid Tumors

Coldrif Cough Syrup banned in Punjab amid child deaths

Contaminated cough syrup tragedy: NHRC steps in, demands investigation

DoP identifies 11,100 Jan Aushadhi Kendras across India as Outdoor Cleaning Sites